Berger Montague PC Investigates Investor Losses Related to RxSight, Inc. (RXST) Following Class Action Filing

Philadelphia, Pennsylvania--(Newsfile Corp. - July 28, 2025) - Berger Montague PC is investigating potential securities fraud claims on behalf of investors in RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).

RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery. Its RxSight system involves the Company's Light Delivery Device (LDD).

On July 8, 2025, RxSight revealed significant declines in LDD sales, LAL utilization, and overall revenue in Q2 2025, also lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz disclosed at that time that "[a]doption challenges over the last few quarters have been a primary reason for the LDD stall."

On this news, RxSight shares fell $4.84, or 37%, to a close of $7.95 per share on July 9, 2025.

If you acquired RxSight stock during the Class Period of November 7, 2024 through July 8, 2025, you may seek lead plaintiff status in the case by September 22, 2025. The lead plaintiff represents other harmed investors in the litigation.

If you are an RxSight investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.

About Berger Montague

Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE. The Firm has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260347